Black Friday saleUp to 70% OFF
Passage Bio, Inc.Passage Bio, Inc.Passage Bio, Inc.

Passage Bio, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

PASG chart


Full chart

PASG upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪31.19 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.1742 USD
Net income (FY)
‪−102.06 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪49.14 M‬
Beta (1Y)
1.75

Employees


Employees (FY)
58
Change (1Y)
−27 −31.76%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.76 M‬ USD

About Passage Bio, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
William Chou
Website
passagebio.com
Headquarters
Philadelphia
Founded
2017
FIGI
BBG00NBK4XF9
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

PASG news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of PASG is 0.5050 USD — it has decreased by −5.78% in the past 24 hours. Watch Passage Bio, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Passage Bio, Inc. stocks are traded under the ticker PASG.
PASG stock has fallen by −14.41% compared to the previous week, the month change is a −17.13% fall, over the last year Passage Bio, Inc. has showed a −15.92% decrease.
We've gathered analysts' opinions on Passage Bio, Inc. future price: according to them, PASG price has a max estimate of 13.00 USD and a min estimate of 3.00 USD. Watch PASG chart and read a more detailed Passage Bio, Inc. stock forecast: see what analysts think of Passage Bio, Inc. and suggest that you do with its stocks.
PASG reached its all-time high on Jun 24, 2020 with the price of 38.2300 USD, and its all-time low was 0.4510 USD and was reached on Nov 19, 2024. View more price dynamics on PASG chart.
See other stocks reaching their highest and lowest prices.
PASG stock is 12.26% volatile and has beta coefficient of 1.75. Track Passage Bio, Inc. stock price on the chart and check out the list of the most volatile stocks — is Passage Bio, Inc. there?
Today Passage Bio, Inc. has the market capitalization of ‪31.19 M‬, it has increased by 3.28% over the last week.
Yes, you can track Passage Bio, Inc. financials in yearly and quarterly reports right on TradingView.
Passage Bio, Inc. is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
PASG earnings for the last quarter are −0.31 USD per share, whereas the estimation was −0.23 USD resulting in a −33.75% surprise. The estimated earnings for the next quarter are −0.22 USD per share. See more details about Passage Bio, Inc. earnings.
Passage Bio, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of ‪1.67 M‬ USD. In the next quarter, revenue is expected to reach 0.00 USD.
PASG net income for the last quarter is ‪−19.34 M‬ USD, while the quarter before that showed ‪−15.99 M‬ USD of net income which accounts for −20.94% change. Track more Passage Bio, Inc. financial stats to get the full picture.
No, PASG doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 25, 2024, the company has 58.00 employees. See our rating of the largest employees — is Passage Bio, Inc. on this list?
Like other stocks, PASG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Passage Bio, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Passage Bio, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Passage Bio, Inc. stock shows the sell signal. See more of Passage Bio, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.